生物銀行技術和全球市場
市場調查報告書
商品編碼
1055086

生物銀行技術和全球市場

Biobanking: Technologies and Global Markets

出版日期: | 出版商: BCC Research | 英文 138 Pages | 訂單完成後即時交付

價格

全球生物樣本庫市場預計將從 2021 年的 611 億美元增長到 2026 年的 762 億美元,預計 2021-2026 年期間的複合年增長率為 4.5%。

本報告對全球生物樣本庫市場進行研究和分析,並提供市場和技術背景、市場機會分析和企業概況等系統資訊。

目錄

第 1 章介紹

  • 調查目標和目的
  • 報告範圍
  • 研究方法和來源
  • 報告方面的新變化
  • 地理分佈
  • 分析師生涯
  • BCC 自定義調查
  • 相關 BCC 調查報告

第 2 章總結與重點

  • 主要亮點

第 3 章市場與技術背景

  • 生物樣本庫概述
  • 生物樣本庫流程
  • 生物樣本庫分類
  • 以疾病為導向/以臨床為基礎的生物樣本庫
  • 基於人群的生物樣本庫
  • 生物樣本庫申請
  • 生物銀行用戶
  • 生物銀行的成本

第 4 章目前世界上的生物樣本庫

  • 概覽
  • 北美主要生物樣本庫
  • 我們所有人的研究計劃
  • 美國國家癌症研究所 (NCI)
  • 國家心肺血液研究所 (NHLBI) 生物樣本和數據存儲庫
  • Kaiser Permanente 研究銀行
  • 密西西比大學醫學中心 (UMMC)
  • 艾滋病/癌症標本資源 (ACSR)
  • 美國國立醫學研究院 (NIGMS) 人類遺傳細胞庫
  • BioMe 生物銀行
  • 加拿大明天的夥伴關係項目 (CanPath)
  • 支持北美生物樣本庫的主要基礎設施
  • 歐洲主要生物樣本庫
  • 英國生物銀行
  • 格拉茨生物銀行
  • 國際癌症研究機構 (IARC) 生物庫
  • 丹麥國家生物銀行
  • 芬根
  • 愛沙尼亞生物樣本庫
  • 解碼遺傳學
  • 支持歐洲生物樣本庫的主要基礎設施
  • BB MRI-ERIC
  • EuroBioBank 網絡
  • RD-連接
  • 亞太地區的主要生物樣本庫
  • 日本生物銀行
  • 維多利亞州癌症生物庫
  • 中國嘉道理生物樣本庫
  • 上海張江生物樣本庫
  • 支持亞太地區生物樣本庫的關鍵基礎設施
  • 其他地區的主要生物樣本庫
  • 卡塔爾生物銀行

第 5 章市場機會分析

  • 市場促進因素
  • 增加對生物樣本庫項目的公共資助
  • 增加在藥物發現和開發中的應用
  • 增加藥品和生物技術的研發支出
  • 分析技術和分析方法的發展
  • 越來越關注主流精準醫學和基因組醫學/臨床基因組研究的興起
  • 生物樣本庫技術的進步
  • 不斷發展的私人生物銀行業務
  • 市場抑制因素
  • 法律和道德問題
  • 可持續性
  • 缺乏標準化/和諧
  • 充分瞭解生物樣本庫活動
  • 全球生物樣本庫行業的 SWOT 分析
  • COVID-19 的影響

第 6 章市場細分:按樣本類型

  • 概覽
  • 生物流體
  • 組織
  • 幹細胞
  • DNA/RNA
  • 其他
  • 市場規模和預測
  • 市場分析

第 7 章市場細分:按應用

  • 概覽
  • 生物銀行
  • 基礎/科學研究
  • 臨床研究/治療劑

第 8 章市場細分:按地區

  • 全球生物樣本庫市場:按地區
  • 北美生物樣本庫市場
  • 歐洲生物樣本庫市場
  • 生物銀行亞太市場
  • 生物樣本庫的其他區域市場

第 9 章市場細分:按所有權類型

  • 概覽
  • 政府/公共部門提供者
  • 學術機構/大學
  • 非營利組織
  • 私人組織
  • 市場規模和預測
  • 市場分析

第 10 章專利審查/新發展

  • 專利審查
  • 新發展

第 11 章公司簡介

  • AGILENT TECHNOLOGIES INC.
  • AMGEN, INC.
  • ASTRAZENECA PLC
  • AVANTOR INC.
  • AZENTA LIFE SCIENCES
  • BIOKRYO GMBH
  • BRUKER CORP.
  • CENTOGENE N.V.
  • HAMILTON CO.
  • INDIVUMED GMBH
  • MERCK KGAA
  • QIAGEN N.V.
  • TECAN GROUP LTD.
  • THERMO FISHER SCIENTIFIC INC.

第 12 章附錄:首字母縮略詞

Product Code: BIO084C

Highlights:

The global market for biobanking is estimated to increase from $61.1 billion in 2021 to $76.2 billion by 2026, at a compound annual growth rate (CAGR) of 4.5% during 2021-2026.

The global market for government agencies/public sector providers owned biobanking is estimated to increase from $24.7 billion in 2021 to $30.1 billion by 2026, at a CAGR of 4.1% during 2021-2026.

The global market for private organizations owned biobanking is estimated to increase from $8.0 billion in 2021 to $10.8 billion by 2026, at a CAGR of 6.3% during 2021-2026.

Report Scope:

This report aims to provide a comprehensive study of the global market for biobanking. It provides a detailed description of the different types of biobanks (disease-oriented/clinical based and population-based) worldwide. The biobanking market is segmented based on their application as basic/scientific research and clinical research/therapeutics. Each application segments' historical and projected market revenues are provided in the report. The global market for biobanking is also segmented based on sample type (as biofluids, tissue, stem cells, DNA/RNA and others) and ownership types (government agencies/public sector providers, academic institutes/universities, non-profit organizations and private organizations). The market revenue for each geographical segment, including North America, Europe, Asia-Pacific and Rest of the World (ROW), have also been provided in the report.

For an in-depth understanding of the market, profiles of market participants are also part of this report. This report also discusses driving and restraining factors and key trends in the biobanking market.

This research covers biobanks dealing with basic science and clinical research. Forensic science, paternity testing, cryopreservation facilities or screening disease testing for newborns and fertility clinics dealing with ovum, sperm and embryo biobanks are not covered in this report. Transplantation and graft-related biobanks dealing with heart valves, cornea and cartilage/tendon are also not covered. Tissue banks for orthopedic, spine, dental, maxillofacial surgery and stem cells biobank for regenerative medicine are also not covered in this report.

Report Includes:

  • 22 data tables and 29 additional tables
  • An up-to-date review and analysis of the global markets for biobanking technologies
  • Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Highlights of the upcoming market potential for biobanking technologies, and areas of focus to forecast this market into various segments and sub-segments
  • In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for biobanking products
  • Evaluation and forecast the overall market size for biobanks, forecasted growth trends, and corresponding market share analysis by sample type, application, ownership type, and region
  • Identification of novel biobanking products and promising new technologies still in the development and testing stage and assess the probability that they will be commercialized successfully in the next five years
  • Review of emerging companies and the leading competitors in the prevailing biobanking industry
  • Insight into recent patent activities on biobanking techniques, R&D activities, clinical trials under process, and selected list of biobanking studies
  • Descriptive company profiles of the major global players, including Agilent Technologies Inc., AstraZeneca plc, Bruker Corp., Hamilton Co., Merck KGaA, Qiagen N.V., and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology and Information Sources
  • What's New in This Report?
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Key Highlights

Chapter 3 Market and Technology Background

  • Biobank Overview
  • The Process of Biobanking
  • Classification of Biobanks
  • Disease-Oriented/Clinical Based Biobanks
  • Population-Based Biobanks
  • Applications of Biobanks
  • Users of Biobanks
  • Biobanking Costs

Chapter 4 Current Biobanks Worldwide

  • Overview
  • Leading Biobanks in North America
  • All of Us Research Program
  • National Cancer Institute (NCI)
  • The National Heart, Lung and Blood Institute (NHLBI) Biologic Specimen and Data Repository
  • Kaiser Permanente Research Bank
  • The University of Mississippi Medical Center (UMMC)
  • The AIDS and Cancer Specimen Resource (ACSR)
  • National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository
  • BioMe Biobank
  • Canadian Partnership for Tomorrow Project (CanPath)
  • Leading Infrastructure That Supports Biobanking in North America
  • Leading Biobanks in Europe
  • The U.K. Biobank
  • Biobank Graz
  • The International Agency for Research on Cancer (IARC) Biobank
  • Danish National Biobank
  • FinnGen
  • Estonian Biobank
  • deCODE Genetics
  • Leading Infrastructure that Supports Biobanking in Europe
  • BBMRI-ERIC
  • EuroBioBank Network
  • RD-Connect
  • Leading Biobanks in the Asia-Pacific Region
  • Biobank Japan
  • Victorian Cancer Biobank
  • China Kadoorie Biobank
  • Shanghai Zhangjiang Biobank
  • Leading Infrastructure that Supports Biobanking in the Asia-Pacific Region
  • Leading Biobanks in the Rest of World
  • The Qatar Biobank

Chapter 5 Analysis of Market Opportunities

  • Market Drivers
  • Increasing Public Funding in Biobank Projects
  • Increasing Applications in Drug Discovery and Development
  • Increasing Pharmaceutical and Biotech R&D Spending
  • Developments in Analytical Technologies and Assay Methods
  • Growing Focus on Mainstream Precision Medicine and Rise of Genomic Medicine/Clinical Genomics
  • Biobanking Technique Advancements
  • Growing Private Biobanking
  • Market Restraints
  • Legal and Ethical Challenges
  • Sustainability
  • Lack of Standardization/Harmonization
  • Insufficient Awareness About Biobanking Activities
  • SWOT Analysis of Global Biobanking Industry
  • Impact of COVID-19

Chapter 6 Market Breakdown by Sample Type

  • Overview
  • Biofluids
  • Tissues
  • Stem Cells
  • DNA/RNA
  • Others
  • Market Size and Forecast
  • Market Analysis

Chapter 7 Market Breakdown by Application

  • Overview
  • Biobanking Applications
  • Basic/Scientific Research
  • Clinical Research/Therapeutics

Chapter 8 Market Breakdown by Region

  • Global Market for Biobanking by Region
  • North American Market for Biobanking
  • Market Analysis
  • Market Revenue by Application
  • Market Revenue by Country
  • European Market for Biobanking
  • Market Analysis
  • Market Revenue by Application
  • Market Revenue by Country
  • Asia-Pacific Market for Biobanking
  • Market Analysis
  • Market Revenue by Application
  • Market Revenue by Country
  • Rest of the World Market for Biobanking
  • Market Analysis
  • Market Revenue by Application
  • Market Revenue by Sub-region

Chapter 9 Market Breakdown by Ownership Type

  • Overview
  • Government Agencies/Public Sector Providers
  • Academic Institutes/Universities
  • Nonprofit Organizations
  • Private Organizations
  • Market Size and Forecast
  • Market Analysis

Chapter 10 Patent Review/New Developments

  • Patent Review
  • New Developments

Chapter 11 Company Profiles

  • AGILENT TECHNOLOGIES INC.
  • AMGEN, INC.
  • ASTRAZENECA PLC
  • AVANTOR INC.
  • AZENTA LIFE SCIENCES
  • BIOKRYO GMBH
  • BRUKER CORP.
  • CENTOGENE N.V.
  • HAMILTON CO.
  • INDIVUMED GMBH
  • MERCK KGAA
  • QIAGEN N.V.
  • TECAN GROUP LTD.
  • THERMO FISHER SCIENTIFIC INC.

Chapter 12 Appendix: Acronyms

List of Tables

  • Summary Table : Global Market for Biobanking, by Ownership Type, Through 2026
  • Table 1 : Selected Cancer-Specific Biobanks
  • Table 2 : Selected Population-Based Biobanks
  • Table 3 : Types of Biobanks Listed on BBMRI-ERIC Database
  • Table 4 : Number of Studies That Obtained/Used Biospecimens in Clinical Trials, by Funder Type
  • Table 5 : Leading Global Biobanks/Projects
  • Table 6 : Selected National Cancer Institute Biobanking Infrastructure
  • Table 7 : Selected Biobanks in North America
  • Table 8 : Selected Infrastructure that Supports Biobanking in the U.S.
  • Table 9 : Selected Biobanks Based in the European Region
  • Table 10 : BBMRI Services
  • Table 11 : BBMRI Projects Launched in 2020
  • Table 12 : Biobanks and Standalone Collection Centers Associated with BBMRI-ERIC
  • Table 13 : Share of Composite Funding Methods for Biobanks in BBMRI Countries
  • Table 14 : Selected Biobanks Based in the Asia-Pacific Region
  • Table 15 : Selected Infrastructure that Supports Biobanking in Asia-Pacific Countries
  • Table 16 : Genomics Platforms and Applications
  • Table 17 : Selected Biobanks Focused on Genome Based Research Projects
  • Table 18 : Selected International Infrastructures/Organizations Supporting the Development of Harmonized Platforms for Biobanks
  • Table 19 : Selected Large Biobanks Contributing to COVID-19 Research
  • Table 20 : Global Market for Biobanking, by Sample Type, Through 2026
  • Table 21 : Oncology Studies Utilizing Tissue Samples
  • Table 22 : Types of Biomarkers Based on Their Applications
  • Table 23 : Biomarkers: Drug Development
  • Table 24 : Applications of Biobank in Cancer Treatment
  • Table 25 : Global Market for Biobanking, by Application, Through 2026
  • Table 26 : Clinical Trials Initiated between 2015 and 2021, by Condition
  • Table 27 : Global Market for Biobanking, by Region, Through 2026
  • Table 28 : North American of Biobanking Studies, by Funder Type
  • Table 29 : North American Market for Biobanking, by Application, Through 2026
  • Table 30 : North American Market for Biobanking, by Country, Through 2026
  • Table 31 : Selected Biospecimen Based Scientific Initiatives in Europe
  • Table 32 : European Market for Biobanking, by Application, Through 2026
  • Table 33 : European Market for Biobanking, by Country, Through 2026
  • Table 34 : Demographic and Healthcare Statistics for Selected European Countries
  • Table 35 : Asia-Pacific Market for Biobanking, by Application, Through 2026
  • Table 36 : Asia-Pacific Market for Biobanking, by Country, Through 2026
  • Table 37 : RoW Market for Biobanking, by Application, Through 2026
  • Table 38 : RoW Market for Biobanking, by Sub-region, Through 2026
  • Table 39 : Selected Government-Owned Biobanks
  • Table 40 : Selected Academic Institutes/University Owned Biobanks
  • Table 41 : Selected Nonprofit Organization-Owned Biobanks
  • Table 42 : Selected Private Biobank Organizations
  • Table 43 : Global Market for Biobanking, by Ownership Type, Through 2026
  • Table 44 : Patents Issued on Biobanking Techniques, 2015-2021
  • Table 45 : Selected Biobanking Studies, 2018-2021
  • Table 46 : Clinical Trials Initiated between 2015 and 2021 Involving Biobanks, by Therapeutic Area
  • Table 47 : Hamilton: Automated Sample Management Solutions
  • Table 48 : Qiagen: Biobanking Portfolio
  • Table 49 : Thermo Fisher Scientific: Biobanking Solutions
  • Table 50 : Acronyms Used in the Global Biobanking Industry

List of Figures

  • Summary Figure A : Global Market for Biobanking, by Ownership Type, 2019-2026
  • Summary Figure B : Global Market Shares of Biobanking, by Ownership Type, 2020
  • Figure 1 : Some Common Aims of Biobanks
  • Figure 2 : Biobank Sample/Data Types
  • Figure 3 : Flow of Biospecimens and Data Through the Biobanking Infrastructure
  • Figure 4 : Number of Clinical Trials Using Biospecimens, 2014-2021
  • Figure 5 : Places that Create/Use Biobanks
  • Figure 6 : Distribution of Operating Costs for Academic Biobanks
  • Figure 7 : Genetic Data Release Timeline, the U.K. Biobank
  • Figure 8 : Share of FinnGen Expenditure for the First Three Years of the Study, 2020
  • Figure 9 : Publications Referencing Biobanking, 2011-2021
  • Figure 10 : Drug Development Cost Statistics and Trends
  • Figure 11 : Share of Biobanks Collaboration on BBMRI-ERIC Database, by Type
  • Figure 12 : SWOT Analysis of Global Market for Biobanking
  • Figure 13 : Global Market for Biobanking, by Sample Type, 2019-2026
  • Figure 14 : Global Market Shares of Biobanking, by Sample Type, 2020
  • Figure 15 : Biospecimens Paving the Way for Personalized Theory
  • Figure 16 : Global Market for Biobanking, by Application, 2019-2026
  • Figure 17 : Global Market Shares of Biobanking, by Application, 2020
  • Figure 18 : Global Market for Biobanking, by Region, 2019-2026
  • Figure 19 : Global Market Shares of Biobanking, by Region, 2020
  • Figure 20 : North American Market for Biobanking, by Application, 2019-2026
  • Figure 21 : North American Market for Biobanking, by Country, 2019-2026
  • Figure 22 : European Market for Biobanking, by Application, 2019-2026
  • Figure 23 : European Market for Biobanking, by Country, 2019-2026
  • Figure 24 : Top Three Areas of Expertise of Germany Biobanking Ecosystem
  • Figure 25 : Top Three Areas of Expertise of the U.K. Biobanking Ecosystem
  • Figure 26 : Top Three Areas of Expertise of the Netherlands Biobanking Ecosystem
  • Figure 27 : Health Expenditures per Capita for Selected European Countries, 2015-2019
  • Figure 28 : Asia-Pacific Market for Biobanking, by Application, 2019-2026
  • Figure 29 : Asia-Pacific Market for Biobanking, by Country, 2019-2026
  • Figure 30 : Health Expenditures per Capita for Selected Asia-Pacific Countries, 2015-2019
  • Figure 31 : RoW Market for Biobanking, by Application, 2019-2026
  • Figure 32 : RoW Market for Biobanking, by Sub-region, 2019-2026
  • Figure 33 : Global Market for Biobanking, by Ownership Type, 2019-2026
  • Figure 34 : Global Market Shares of Biobanking, by Ownership Type, 2020
  • Figure 35 : Clinical Trials on Biobanking, 2015-2021
  • Figure 36 : Agilent: Annual Revenue, 2018-2020
  • Figure 37 : Agilent: Revenue Share, by Segment, 2020
  • Figure 38 : Amgen: Annual Revenue, 2018-2020
  • Figure 39 : AstraZeneca: Annual Revenue, 2018-2020
  • Figure 40 : Avantor: Annual Revenue, 2018-2020
  • Figure 41 : Azenta Life Sciences: Annual Revenue, 2018-2020
  • Figure 42 : Bruker: Annual Revenue, 2018-2020
  • Figure 43 : Bruker: Revenue Share, by Segment, 2020
  • Figure 44 : Centogene: Annual Revenue, 2018-2020
  • Figure 45 : Centogene: Revenue Share, by Segment, 2020
  • Figure 46 : Merck: Annual Revenue, 2018-2020
  • Figure 47 : Qiagen: Annual Revenue, 2018-2020
  • Figure 48 : Tecan: Annual Revenue, 2018-2020
  • Figure 49 : Thermo Fisher Scientific: Annual Revenue, 2018-2020
  • Figure 50 : Thermo Fisher Scientific: Revenue Share, by Segment, 2020